F-1: Cuprina Holdings Files for Nasdaq IPO to Advance Wound Care and Cosmeceutical Products

Cuprina Holdings, a Singapore-based biomedical company, has filed for an initial public offering on the Nasdaq Capital Market to fund the development and commercialization of its chronic wound care and cosmeceutical products.

Summary

• Cuprina Holdings, a biomedical and biotechnology company based in Singapore, is seeking to raise capital through an initial public offering of 3,750,000 Class A Ordinary Shares on the Nasdaq Capital Market.
• The company specializes in developing and commercializing innovative products for chronic wound management and operates in the health and beauty sectors.
• Cuprina's current product line includes medical-grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand, used for biological debridement of chronic wounds.
• The company also has two lines of chronic wound care products in its pipeline, including collagen dressings derived from bullfrog skin and products utilizing medical leeches for wound treatment, with commercial availability expected in 2025 and 2026.
• For its cosmeceuticals business, Cuprina introduced three products in 2023, including a hydrating balm, a muscle energy cream, and a pain relief muscle patch.
• The company plans to expand its sales and establish physical operations in the Middle East and mainland China in 2025 and 2026.
• Cuprina reported revenues of S$58,504, S$56,599, S$100,773 (US$76,424), and S$41,005 (US$30,184) for the years ended December 31, 2021, 2022, 2023 and six months ended June 30, 2024, respectively, while incurring net losses of S$519,686, S$1,094,516, S$1,119,555 (US$849,048) and S$704,026 (US$518,238), respectively, for the same periods.
• The company intends to use the net proceeds from the IPO for market expansion, research and development, brand awareness, equipment investment, and loan repayment.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has innovative products and growth potential, it also faces significant financial challenges and risks. The sentiment is neutral to slightly negative due to the company's history of losses and reliance on external funding.

Positives

• Cuprina has a focus on developing functionally specific chronic wound care products designed to address the major stages of the wound healing process.
• The company has access to innovative technology through a licensing agreement with Nanyang Technological University for collagen derived from bullfrog skin.
• Cuprina has a commitment to sustainability, utilizing materials derived from natural sources and valorizing waste streams.
• The company has a loyal and growing customer base, primarily consisting of major public and private hospitals and clinics in Singapore.
• Cuprina has a strong leadership team with in-depth knowledge and expertise in the biomedical and biotechnology fields.
• The company has attained ISO 13485:2016 standards for Quality Management Systems and Manufacturing Processes and Controls for its manufacturing facility in Singapore.

Negatives

• Cuprina is an early-stage company with a history of losses and expects to incur losses in the future.
• The company has recorded net current liabilities as of December 31, 2021, 2022, 2023 and June 30, 2024.
• The company had net operating cash outflows for the years ended December 31, 2021, 2022, 2023, and six months ended June 30, 2024.
• The company relies heavily on R&D partners for know-how on design, manufacturing methods and formulation of its products.
• The company's maggot-based chronic wound care products are not currently protected by any pending patent application nor any unexpired patent.

Risks

• The company's business and future growth prospects rely on industry development and consumer demand for its products.
• The company's revenue growth for a particular period is difficult to predict, and a shortfall in forecasted revenues may harm its operating results.
• The company may not be able to develop new products that are competitive or successful in the markets it has entered or plans to enter, in a timely manner or at all.
• The development and sale of certain of the company's pipeline products are heavily dependent on certain agreements with R&D partners and the termination of any of these agreements could harm its business.
• The company may not be able to successfully commercialize its pipeline products.
• The company is subject to various governmental regulations relating to the labeling, marketing and sale of its products.
• The company may be found to infringe on or violate the intellectual property rights of others.
• The company is dependent on a few of its major customers and suppliers.
• The company is exposed to foreign exchange risks.
• The company is subject to credit risk arising from some of its customers.
• The company may not maintain the listing of its Class A Ordinary Shares on the Nasdaq which could limit investors ability to make transactions in Class A Ordinary Shares and subject it to additional trading restrictions.
• The trading price of the company's Class A Ordinary Shares may be volatile, which could result in substantial losses to investors.
• The dual-class structure of the company's ordinary shares may adversely affect the trading market for its Class A Ordinary Shares.
• The sale or availability for sale of substantial amounts of the company's Class A Ordinary Shares could adversely affect their market price.
• The company is subject to risks associated with joint ventures or strategic alliances.
• The company faces risks related to heightened inflation, recession, financial and credit market disruptions and other economic conditions.
• The company is dependent on its key management and skilled personnel for its continued success and growth.
• The company may need additional capital, and it may be unable to obtain such capital in a timely manner or on acceptable terms, or at all.
• The company is an emerging growth company and may take advantage of certain reduced reporting requirements.
• The company is a foreign private issuer and is exempt from certain provisions applicable to United States domestic public companies.
• The company will be a controlled company within the meaning of the rules of Nasdaq and, as a result, will rely on exemptions from certain corporate governance requirements that provide protection to shareholders of other companies.
• The company may be found to infringe on or violate the intellectual property rights of others.
• The company is subject to various governmental regulations relating to the labeling, marketing and sale of its products.
• The company may not be able to obtain or maintain adequate reimbursement or insurance coverage for its medical products.
• The company may be subject to potential liability and negative publicity if its employees, distributors, customers, suppliers or other business partners engage in illegal, fraudulent, improper or unethical conduct.
• Defects, failures or quality issues associated with the company's products could materially adversely affect its reputation, business, results of operations and financial condition.
• Failure to maintain effective pricing strategies and any downward changes in the pricing of the company's products could have a significant adverse effect on its business and results of operations.
• The company relies on third parties to manufacture and supply its products, and it may encounter delays or incur additional costs when it adds/replaces manufacturers and suppliers for its products.
• Negative publicity involving the company, the industry it operates in, its brands and products, its shareholders, directors, officers, or employees, as well as distributors, suppliers or other parties it collaborates with, could have an adverse effect on its business and reputation.
• The company is dependent on a few of its major customers and suppliers.
• The reduction or discontinuation of government grants currently available to the company may have a material adverse effect on its business operations and financial condition.
• The company's historical growth and performance may not be indicative of its future growth and performance.
• The company plans to expand its business operations into new geographic markets including mainland China and Hong Kong, which could subject it to rules, regulations and influence of regulators in those jurisdictions.
• The company may need to incur additional costs in the event of disputes, claims, defects or delays.
• The company faces risks related to heightened inflation, recession, financial and credit market disruptions and other economic conditions.
• The company is subject to credit risk arising from some of its customers, and its failure to collect on accounts receivable from its customers may have a material adverse effect on its business operations and financial condition.
• The company requires adequate working capital for its operations.
• The company is dependent on a few of its major customers.
• The company is dependent on a few of its major suppliers.

Future Outlook

The company intends to continue to grow its business and further strengthen its market position by expanding into new geographic markets, expanding its product portfolio through development and innovation, strengthening brand awareness, and attracting and retaining a talented workforce.

Management Comments

• We believe what sets us apart is our focus on developing functionally specific chronic wound care products designed to address the major stages of wound healing process, from chronic to closure.
• Our chronic wound care products, including both our existing commercialized products and forthcoming products in our pipeline, are poised to benefit from escalating global market demand.
• We either self-develop our chronic wound care products or co-develop them through technology licensing agreements or research collaboration with a renowned research university.

Industry Context

The chronic wound care market is experiencing growth due to an aging population and the rise in comorbidities such as diabetes and obesity. Cuprina's focus on developing innovative and cost-effective solutions positions it to benefit from this market trend.

Comparison to Industry Standards

• The company's MEDIFLY product competes with traditional surgical debridement methods and other biological debridement options, such as enzymatic debriders.
• The company's collagen dressings, derived from bullfrog skin, are a novel approach compared to traditional collagen dressings derived from bovine or porcine sources.
• The company's use of medical leeches for wound treatment is a traditional method that is being modernized and advanced with modern medical standards and processes.
• The company's cosmeceutical products compete with a wide range of skincare and pain relief products available in the market, but the company aims to differentiate itself through the use of bullfrog collagen in future products.

Related Party Transactions

• The company has related party transactions with Cuprina Holding Pte. Ltd., Jimmy Lee Peng Siew, David Quek Yong Qi, Bryan Teo Yingjie, Rachel Lee Lin, Cuprina Farm Sdn. Bhd., Cuprina Pollination Pte. Ltd., Pestoniks Innovations Pte. Ltd., Cuprina MENA Co., Ltd., Dorea Quek En Qi, De Guzman Caroline Francesca Lee Ling and iCapital Holdings (SG) Pte. Ltd.
• These transactions include advances for working capital purposes, payments made on behalf of related parties, and share subscriptions.

Stakeholder Impact

• Shareholders: The IPO provides an opportunity for investors to participate in the growth of the company, but also carries risks due to the company's financial situation and market competition.
• Employees: The company's growth plans may create new job opportunities, but also require a talented and professional workforce.
• Customers: The company's innovative products may provide better treatment options for chronic wounds and cosmeceutical products.
• Suppliers: The company's expansion may lead to increased demand for raw materials and manufacturing services.
• Creditors: The company's loan repayment plans may impact its financial stability and ability to meet its obligations.

Next Steps

• The company plans to expand its sales and establish physical operations in the Middle East and mainland China in 2025 and 2026.
• The company expects to receive a 510(k) clearance for its MEDIFLY products by the end of 2025.
• The company intends to present its 510(k) submission to the FDA for its bullfrog collagen sponge dressings in 2025.
• The company plans to explore the possibility of developing a range of potential cosmeceutical product candidates incorporating bullfrog collagen with a view to making them commercially available between 2025 and 2028.

Key Dates

Keywords

wound care, biomedical, biotechnology, cosmeceuticals, maggot debridement therapy, collagen dressings, medical leeches, Nasdaq IPO, MEDIFLY, bullfrog collagen